Meeting
2022 ASCO Annual Meeting
Neoadjuvant nivolumab in early-stage non–small cell lung cancer (NSCLC): Five-year outcomes.
Authors
Samuel Rosner
Johns Hopkins University, Baltimore, MD
Samuel Rosner , Joshua E. Reuss , Marianna Zahurak , Janis M. Taube , Stephen Broderick , David Randolph Jones , Jamie E. Chaft , Patrick M. Forde
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02259621
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8537)
DOI
10.1200/JCO.2022.40.16_suppl.8537
Abstract #
8537
Poster Bd #
164
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant nivolumab (N) plus cisplatin (C)/pemetrexed (P) or cisplatin /gemcitabine (G) in resectable NSCLC.
First Author: Ralph Zinner
Poster
2018 ASCO Annual Meeting
Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.
First Author: Nathaniel R. Evans
Poster
2022 ASCO Annual Meeting
Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study.
First Author: Yara L. Verschoor
Poster
2020 ASCO Virtual Scientific Program
CT and PET radiomic features associated with major pathologic response to neoadjuvant immunotherapy in early-stage non-small cell lung cancer (NSCLC).
First Author: Erica C. Nakajima